Rapt Therapeutics reports Q2 EPS (66c), consensus (78c)

Reports Q2 revenue $0 vs $886,000 last year. “We continue to remain focused on our Phase 2 trials for RPT193 in atopic dermatitis and asthma. We anticipate reporting top-line data from our Phase 2b trial in AD in mid-2024 and we continue to enroll our Phase 2a trial in asthma. These are the first two indications in what we believe will be a significant franchise for our promising oral small molecule drug in inflammatory diseases,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “Separately, our Phase 2 trial of FLX475 continues to progress and we anticipate providing an update later this year. With our current cash balance, we expect to be able to support our operations through mid-2025.”